Prilenia

About:

Prilenia is a clinical-stage biotech company that develops novel treatments for neurodegenerative and neurodevelopmental disorders.

Website: https://www.prilenia.com

Twitter/X: PrileniaTx

Top Investors: Sands Capital Ventures, Forbion Capital Partners, Morningside Venture Investments, Amplitude Venture Capital, Sectoral Asset Management

Description:

Prilenia is a clinical-stage biotech company that develops novel treatments for neurodegenerative and neurodevelopmental disorders. Its lead asset is Pridopidine, a n oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children. The company was founded in 2018 and is based in Israel, the Netherlands, and Boston.

Total Funding Amount:

$106M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Herzliya, Tel Aviv, Israel

Founded Date:

2018-01-01

Contact Email:

info(AT)prilenia.com

Founders:

Michael Hayden

Number of Employees:

11-50

Last Funding Date:

2021-11-03

IPO Status:

Private

Industries:

© 2025 bioDAO.ai